Abstract
Children at high risk for sudden cardiac death (SCD) receive implantable cardioverter-defibrillators (ICD) for prevention, but the cost effectiveness of ICDs in children at intermediate risk is unclear. Our objective was to create a cost-effectiveness model to compare costs and outcomes in children at risk of SCD, with and without ICD. Utilizing hypertrophic cardiomyopathy as the proxy disease, a theoretical cohort of 8150 children was followed for 69 years. Model inputs were derived from the literature, with an incremental cost-effectiveness ratio (ICER) willingness-to-pay threshold of $100,000/quality-adjusted life year (QALY) used to delineate cost effectiveness. Outcomes included prevalence of severe neurological morbidity (SNM), SCD, cost, and QALYs. In children at intermediate risk of SCD (4–6% over 5 years), ICD resulted in 56 fewer cases of SNM, 2686 fewer deaths. In children at high risk (> 6% over 5 years), ICD placement resulted in 74 fewer cases of SNM and 3663 fewer deaths from cardiac causes. The costs of ICD were higher, but placement was cost effective with an ICER of $3009 per QALY in intermediate risk children, but ICD therapy was a dominant strategy in high-risk children. Sensitivity analysis demonstrated ICD placement was cost-effective until the annual probability of SCD was < 0.22%. The model was robust over a wide range of values. For children at risk of SCD, prophylactic ICD implantation is cost effective, resulting in improved outcomes and increased QALYs, despite increased costs. These findings highlight the economic benefits of ICD utilization in this population.
Similar content being viewed by others
References
Desai MY, Smedira NG, Dhillon A, Masri A, Wazni O, Kanj M, Sato K, Thamilarasan M (2018) Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria. J Thorac Cardiovasc Surg 156(750):759.e3. https://doi.org/10.1016/j.jtcvs.2018.03.150
Zamorano JL, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Piepe PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H, O’Mahony C, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Alfonso F, Basso C, Cardim NM, Gimeno JR, Heymans S et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779
Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P (2018) Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Cirr Arrhythm Electrophysiol 11:1–9
Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353:1471–1480
Ingles J, Mcgaughran J, Scuffham PA, Atherton J, Semsarian C, Prince R, Hospital A (2012) A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 98:625–630
Anon. Population Estimates, Persons under 18 years, percent. United States Census Bur 2018. https://www.census.gov/quickfacts/fact/table/US/AGE295218. Accessed Jan 9 2019
Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Iii NAME, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS (2013) Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61:1527–1535. https://doi.org/10.1016/j.jacc.2013.01.037
Maron BJ, Spirito P, Shen W, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Winters SL (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. J Am Med Assoc 298:405–412
Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H (2010) DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 31:926–935
Lee DS, Green LD, Liu PP, Dorian P, Ms C, Newman DM, Grant FC, Ms C, Tu JV, Alter DA (2003) Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 41:1573–1582. https://doi.org/10.1016/S0735-1097(03)00253-5
Berdowski J, Kuiper MJ, Dijkgraaf MGW, Tijssen JGP, Koster RW (2010) Survival and health care costs until hospital discharge of patients treated with onsite, dispatched or without automated external defibrillator. Resuscitation 81:962–967. https://doi.org/10.1016/j.resuscitation.2010.04.013
Cram P, Vijan S, Katz D, Fendrick AM (2005) Cost-effectiveness of in-home automated external defibrillators for individuals at increased risk of sudden cardiac death. J Gen Intern Med 20:251–258
Anon. Consumer price index: medical component. Bur Labor Stat 2019. https://www.bls.gov/cpi/home.htm. Accessed Jan 6 2019
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Russell LB, Siegel JE, Ganiats TG (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. Second panel on cost-effectiveness in health and medicine. JAMA 316:1093–1103
Anderson BR, McElligott S, Polsky D, Vetter VL (2014) Electrocardiographic screening for hypertrophic cardiomyopathy and long QT syndrome: the drivers of cost-effectiveness for the prevention of sudden cardiac death. Pediatr Cardiol 35:323–331
Cobbe SM, Dalziel K, Ford I, Marsden AK (1996) Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest. Br Med J 312:1633–1637
Larson S, Hallas-Muchow L, Hewitt A, Pettingell S, Anderson L, Moseley CR, Sowers M, Lee Fay M, Aiken F, Agosta J, Kardell Y, Smith D. In-home and residential long-term supports and services for persons with intellectual or developmental disabilities: status and trends through 2016. National Residential Information Systems Project (RISP); 2018
Anon. Income and Poverty in the United States: 2017. United States Census Bur; 2017
Munnell A (2015) The average retirement age—an update. Issue in Brief 15-4. Center for Retirement Research at Boston College, Chestnut Hill
Anon. Mortality in the United States, 2017: NCHS Data Brief No. 328. Centers Dis Control Prev 2018. https://www.cdc.gov/nchs/products/databriefs/db328.htm
Smith T, Jordaens L, Theuns DAMJ, Van Dessel PF, Wilde AA, Hunink MGM (2013) The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J 34:211–219
Bunch JT, White RD, Gersh BJ, Meverden RA, Hodge DO, Ballman KV, Hammill SC, Shen W, Packer DL (2003) Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 348:2626–2633
Funding
None.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation and data collection were performed by MBH and ARH. Data analysis was performed by MBH and ARH. The first draft of the manuscript was drafted by MBH. SB critically examined the manuscript for important intellectual content. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Haag, M.B., Hersh, A.R., Toffey, D.E. et al. Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children with Cardiac Conditions Associated with Risk for Sudden Cardiac Death. Pediatr Cardiol 41, 1484–1491 (2020). https://doi.org/10.1007/s00246-020-02395-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-020-02395-y